Abcam (ABCM) acquires BioVision, Inc

Abcam, a global innovator in life sciences reagents and tools, today announced the successful acquisition of BioVision.

Image credit: BioVision

Across the life sciences sector, the events of the last 18 months have amplified the need for efficient workflows and robust data generation, to enable the faster delivery of positive outcomes for science and health. Widespread access to high-performance, reproducible, off-the-shelf assays and kits has become invaluable to enable the biopharma industry and academia to achieve meaningful advances at pace.

The successful acquisition brings BioVision's product portfolio, capabilities, and 70-strong expert development and manufacturing teams into Abcam. The global research community will gain ready access to this portfolio of biochemical and cell-based assays via Abcam's global commercialization network. We are committed to continuing to support our customers in their research efforts by providing high quality products with personalised support. Please continue to contact BioVision directly, or your usual distributor, to purchase products and for product support. Contact information:


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BioVision Incorporated. (2021, October 28). Abcam (ABCM) acquires BioVision, Inc. News-Medical. Retrieved on November 28, 2021 from

  • MLA

    BioVision Incorporated. "Abcam (ABCM) acquires BioVision, Inc". News-Medical. 28 November 2021. <>.

  • Chicago

    BioVision Incorporated. "Abcam (ABCM) acquires BioVision, Inc". News-Medical. (accessed November 28, 2021).

  • Harvard

    BioVision Incorporated. 2021. Abcam (ABCM) acquires BioVision, Inc. News-Medical, viewed 28 November 2021,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.